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A randomised double-blind placebo-controlled design was employed to investigate the effects of Zn supplementation on cognitive function in 387
healthy adults aged 55–87 years. Several measures of visual memory, working memory, attention and reaction time were obtained using the Cam-
bridge Automated Neuropsychological Test Battery at baseline and then after 3 and 6 months of 0 (placebo), 15 or 30 mg Zn/d. Younger adults
(,70 years) performed significantly better on all tests than older adults (.70 years), and performance improved with practice on some measures.
For two out of eight dependent variables, there were significant interactions indicating a beneficial effect (at 3 months only) of both 15 and 30 mg/d
on one measure of spatial working memory and a detrimental effect of 15 mg/d on one measure of attention. Further work is required to establish
whether these findings generalise to older adults in poorer mental and physical health and with less adequate Zn intake and status than the present
sample.
Zinc: Cognition: Ageing: Cambridge Automated Neuropsychological Test Battery
Dietary intake affects brain function (Fernstrom, 2000) but
there remain gaps in our knowledge of the behavioural effects
of many nutrients, particularly in older adults (Mocchegiani
et al. 2005). There is considerable interest in the potential cog-
nitive benefits from nutritional supplements (see McDaniel
et al. 2002), with some encouraging results, for example,
with B vitamins (Calvaresi & Bryan, 2001), vitamins C and
E (Masaki et al. 2000) and folate (Joyal et al. 1993). One
micronutrient that has received less attention is Zn, a non-
toxic trace element essential for many biochemical activities
and physiological functions (for reviews, see Hambidge,
2000; Salgueiro et al. 2000). As an antioxidant, Zn is import-
ant to the immune, reproductive and central nervous systems
and is present in many areas of the brain, particularly in the
hippocampus and amygdala (Takeda, 2000), influencing
brain structure and function (Black, 1998; Sandstead, 2000,
2003). Zn can only be obtained through the diet (mostly
from meat and fish), the results of Zn deficiency ranging
from slower wound healing to delayed physical and cognitive
development (Hambidge, 2000).
Inadequate Zn nutriture has been identified in both develop-
ing and developed countries, particularly in infants, pregnant
and lactating women and older adults (Briefel et al. 2000;
Penland, 2000; Sandstead, 2000). Zn supplementation studies
in infants and pregnant women have demonstrated benefits in
terms of the physical health, growth rate and cognitive devel-
opment of the infants and babies born to the mothers taking
supplements (for reviews, see Black, 1998; Bhatnagar &
Taneja, 2001; Salgueiro et al. 2002). There have been fewer
studies of Zn supplementation in children and adults and
although improvements in cognitive function have been
observed, methodological issues suggest that further data are
required (Penland, 2000).
As a nutritionally vulnerable group – because of physio-
logical, social, psychological and economic factors – older
adults are especially at risk of Zn deficiency (Blumberg,
1997; McClain et al. 2002). Briefel et al. (2000) reported
that only 44 % of adults over 70 years had an adequate
intake of Zn, and Prasad et al. (1993) concluded from their
study of independent-living older individuals that Zn
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deficiency posed a ‘significant clinical problem’. In view of
evidence from animal studies of links between reduced Zn
in the hippocampus and age-related decline in spatial
memory (for summaries, see Takeda, 2000; Mocchegiani
et al. 2005), it seems surprising that there have been only
two substantial studies of the effects of Zn on cognitive func-
tion in older adults. Ortega et al. (1997) examined 260
Spaniards aged 65–90 years and found that better cognitive
scores were associated with greater dietary intake of a
number of nutrients including Zn, suggesting that ‘zinc may
influence cognitive function’. However, the authors acknowl-
edged that their design was unable to establish cause and
effect or to exclude possible confounding factors. Yaffe et al.
(2004) administered cognitive tests to 2166 adults aged 61–87
years, half of whom had been receiving Zn supplements
(80 mg/d) for several years. There were no significant differ-
ences between groups but the authors noted several limitations
to their study, including the lack of cognitive measures before
supplementation, and the loss of 40 % of participants.
The present study aimed to assess the Zn status of healthy
late middle-aged and older Europeans and to investigate the
effects of Zn supplementation on their cognitive functioning.
Note that even if the sample were not Zn deficient, there
may be advantages in consuming some nutrients at levels
beyond average requirements (Kiely et al. 2001). Moreover,
we need to establish that supra-nutritional doses of Zn have
no adverse effects. This is vital because of the growing use
of dietary supplements, including amongst older individuals
(Canter & Ernst, 2004), and the increasing availability of
foods specifically fortified with Zn (for example, ‘Minute
Maid’ 100 % pure squeezed smooth orange juice and raspberry
with Zn; http://www.minutemaid.co.uk/MM-Raspberry.asp).
The design was a randomised, double-blind, placebo-con-
trolled intervention trial in men and women assigned to one
of three treatments: placebo, 15 mg Zn/d or 30 mg Zn/d for
6 months. Clinical and psychological examinations and
blood and urine samples were taken before intervention, and
after 3 and 6 months of Zn supplementation. Cognitive
function was assessed by the Cambridge Automated
Neuropsychological Test Battery (CANTAB; Morris et al.
1986; Sahakian & Owen, 1992).
Method
Participants
Participants were recruited through posters, leaflets, local tele-
vision and radio, and community groups and organisations ser-
ving older individuals living independently. Two centres
(Coleraine, UK and Clermont-Ferrand, France) recruited
younger participants (55–70 years); two centres (Rome,
Italy and Grenoble, France) recruited older participants (70–
87 years). Volunteers (292 in the younger group; 550 in the
older group) were invited to attend a preliminary session
that included a full medical history and examination, anthro-
pometric measurements, assessment of dietary habits, tobacco
and alcohol consumption, and screening for cognitive impair-
ment and depression (mini-mental state examination (MMSE;
Folstein et al. 1975) and geriatric depression scale (Yesavage
et al. 1983), respectively). Fully informed written consent was
required before taking part in the study. Ethical approval was
obtained from the appropriate ethics committee in each of the
three countries involved in the study. All participants received
their travel expenses and (with the exception of the Italian
sample) a small honorarium for taking part in the study.
Participants were excluded from further involvement in the
study according to the following criteria: (1) tobacco con-
sumption of more than 10 g/d; (2) alcohol consumption of
more than 30 (men) or 20 (women) g/d; (3) unconventional
dietary habits (for example, vegetarians, vegans); (4) use of
a mineral supplement during the preceding 3 months; (5)
use of more than three (55–70 years) or four (70–87 years)
prescription drugs per d; (6) use of antidepressants, laxatives,
or hormone replacement therapy; (7) pathological diseases,
including cancer and diabetes. Inclusion criteria were: (1)
men and women aged between 55 and 87 years; (2) BMI
between 20 and 30 kg/m2; (3) good health; (4) MMSE score
greater than 23; (5) geriatric depression scale score less than
6. For participants satisfying these criteria, a biochemistry
profile was performed, which included a full blood profile
and tests of kidney and liver function. On the basis of these
data, participants were excluded if there was insufficient
renal and hepatic performance, malabsorption or inflammatory
chronic pathologies, and were included if there was negative
serology for the HIV and hepatitis C viruses.
Of the 842 volunteers who were screened, 49 % were not
selected for further participation. Pathological conditions and
the use of medications represented the main reasons why par-
ticipants were excluded, especially for the older adults (for full
details, see Polito et al. 2005). This resulted in 433 partici-
pants (201 younger; 232 older) admitted to the supplemen-
tation phase. During the 6-month study, forty-three
participants dropped out (thirteen younger; thirty older). Com-
pliance was less than 80 % for three older participants and so
they were also excluded. Thus, a total of 387 participants (188
younger; 199 older), with approximately equal numbers of
males and females (196 and 191, respectively), successfully
completed the full Zn supplementation study.
The majority of the 387 participants were retired from full-
time work (68·1 % of the younger group; 95·0 % of the older
group). Participants’ education was categorised into four
levels: no formal education; primary education; secondary
education; tertiary education. The percentages of younger par-
ticipants at each level of education were 0·0, 16·0, 46·3 and
37·8, respectively. The corresponding percentages of older
participants were 0·5, 28·1, 53·3 and 18·1. As expected,
younger participants received significantly more formal edu-
cation than older participants (x2 21·89; df 3; P,0·001).
Participants were assigned to one of three levels of Zn sup-
plementation (placebo or 0 mg/d, 15 mg/d and 30 mg/d)
according to the same standardised random order in each
centre. The larger dose was determined on the basis of an
average adult intake of about 10 mg Zn/d and a tolerable
upper intake level for adults of 40 mg Zn/d (Food and Nutri-
tion Board & Institute of Medicine, 2000). Table 1 shows
the distribution of participants as a function of age group,
treatment and sex and provides background measures col-
lected at baseline (i.e. before supplementation) for each age
group and (subsequent) treatment. Participants’ daily intake
of Zn was estimated from their detailed records of food and
drink consumed over a 4 d period (Andriollo-Sanchez et al.
2005). (Data were unavailable for five participants.) Serum,
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erythrocyte and urinary Zn levels were determined by flame
atomic absorption spectrometry using standard methodology
(Arnaud et al. 1986). (Data were unavailable for two, twelve
and five participants, respectively.) Erythrocyte Zn levels are
representative of long-term Zn status (Vitoux et al. 1999).
Cognitive measures (Cambridge Automated
Neuropsychological Test Battery)
CANTAB was selected to provide measures of cognitive func-
tion for a number of reasons. It is sensitive to cognitive
changes due to a wide range of brain disorders and medi-
cations (Fray & Robbins, 1996; Fray et al. 1996). The tests
have brain-to-behaviour reliability (Luciana & Nelson,
2002). Parallel versions are available for repeated measures,
with high test–retest reliability (Semple & Link, 1991;
Louis et al. 1999). Construct validity has been obtained
from studies of neurological and psychiatric patients with dis-
orders affecting specific brain regions (Elliott & Sahakian,
1995; Owen et al. 1996). CANTAB has been used extensively
in clinical trials (Louis et al. 1999) and in research with older
adults (Robbins et al. 1994). The tests are graded to allow for
a wide range of ability whilst avoiding floor and ceiling
effects. CANTAB assesses cognition using a computer to
ensure standardised presentation and feedback with non-
verbal stimuli and touch-screen methodology, rendering it
suitable for research across different European centres.
Finally, both speed and accuracy are recorded (on the import-
ance of this with regard to investigations of nutritional stres-
sors, see Penland, 2000).
Visual memory was tested by pattern recognition memory
(PRM; requiring temporal lobe–hippocampal–amygdala
activation), working memory was tested by spatial span
and spatial working memory (SWM; requiring both temporal
and frontal lobe activation), and attention was tested by
reaction time and matching to sample visual search (MTS;
activating several brain regions including fronto-striatal cir-
cuitry) (for a summary of supportive evidence, see Robbins
et al. 1997).
Procedure
Zn supplementation (0, 15 or 30 mg/d) was administered as
zinc gluconate, participants taking two tablets at the same
time each day (usually after breakfast) for 6 months. (Tablets
were identified by a code so that neither the experimenter nor
the participant knew the dose. The code was not broken until
the study had been completed and all the data had been
entered into computer files ready for analysis.) Cognitive func-
tion was assessed in the laboratory at baseline (before sup-
plementation) and after 3 and 6 months of supplementation,
using different (parallel) versions of the CANTAB tests on
each occasion. Participants fasted overnight for 12 h before
blood and urine samples were taken on each of these
occasions to determine Zn levels.
The CANTAB tests were administered after participants had
eaten breakfast in the laboratory and took approximately
35–40 min. Experimenters from each of the four testing centres
had previously attended a 2 d training course at Cambridge Cog-
nition Limited (Cambridge, UK), to ensure that the tests were
administered in exactly the same way. In addition, standardised
verbal instructions were taken verbatim from the CANTAB test
manual, which was available in English, French and Italian.
The procedure was identical on each of the three testing
occasions. Stimulus presentation was computer-controlled
and responses were obtained using a touch-sensitive screen
and also a large press-pad for some of the tests, placed
0·15 m from the screen. Participants were seated approxi-
mately 0·5 m from the screen. They were first introduced to
the equipment and familiarised with the response methodology
by completing a motor screening test: participants responded
to a series of crosses on the screen by touching each one
with the index finger of their preferred hand as soon as a
cross appeared. If their response was accurate, auditory feed-
back was presented, the cross disappeared and the next one
was presented after a short delay. Following successful com-
pletion of this task (ten crosses), the main cognitive tests
were presented, always in the following order.
Pattern recognition memory. In the study phase, partici-
pants were shown a series of twelve simple abstract coloured
Table 1. Numbers of younger and older participants assigned to each of three Zn treatments (0, 15 and 30 mg/d), with age, screening test scores and
Zn measures at baseline
(Mean values and standard deviations)
Younger Older
0 mg/d 15 mg/d 30 mg/d 0 mg/d 15 mg/d 30 mg/d
Measure Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
n 63 60 65 67 66 66
Males (n) 32 30 31 35 34 34
Females (n) 31 30 34 32 32 32
Age (years) 62·3 4·09 61·4 4·55 61·7 4·57 74·2 3·58 74·3 3·91 74·6 3·89
MMSE 29·0 1·18 28·7 1·23 28·6 1·30 28·6 1·66 28·2 1·84 28·7 1·50
GDS 1·44 1·46 2·03 1·46 2·11 2·08 1·85 1·52 1·88 1·49 2·12 1·43
Zn intake (mg/d) 10·56 3·19 10·73 5·43 10·35 3·57 12·09 6·19 10·17 3·50 11·69 5·28
Serum Zn (mmol/l) 13·20 1·65 12·74 1·48 13·01 1·34 13·21 1·69 13·29 1·84 13·14 1·64
Erythrocyte Zn (mmol/l) 232·4 54·3 216·9 54·4 219·4 58·0 196·1 56·0 200·1 54·4 208·7 59·4
Urinary Zn (mmol/mmol creatinine) 0·72 0·37 0·63 0·28 0·61 0·25 1·13 1·12 1·12 0·72 0·86 0·38
MMSE, mini-mental state examination (Folstein et al. 1975); GDS, geriatric depression scale (Yesavage et al. 1983).
For details of subjects and procedures, see p. 753.
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patterns that could not easily be assigned verbal labels. Each
pattern was presented for 3 s and appeared inside a white
box in the centre of the screen. In the test phase, twelve
pairs of target-distractor patterns appeared serially, with one
item to the left and the other to the right of the screen
centre, and for each pair participants were required to touch
the pattern seen during the study phase. Visual feedback on
accuracy was provided (green tick or red cross for correct or
incorrect responses). Distractor patterns differed from target
patterns in form but not in colour. Targets in the test phase
were presented in the reverse order to the original order at
study. This entire procedure was then repeated with a new
set of twelve patterns followed by twelve pairs of patterns
for recognition. Both response accuracy (the total number of
correctly recognised patterns out of twenty-four, expressed
as a percentage) and mean latency in ms for correct trials
were measured.
Spatial span. In this task, based on the Corsi Block Tapping
task (Milner, 1971), a set of nine white boxes was shown on the
screen. Some of these boxes then changed colour for 3 s one by
one in a random sequence. A tone then indicated to participants
that they should touch each of the highlighted boxes in the same
order as they were originally coloured by the computer. The task
began with a sequence of two boxes and then increased in length
by one box each trial if the participant correctly recalled the
sequence. After an incorrect attempt, another sequence of the
same length was presented. This continued until the participant
had failed three consecutive trials at any one length. Thus three
attempts were allowed at each level up to a maximum of nine
boxes. The dependent measure was the highest level at which
the participant correctly recalled at least one sequence of boxes.
Spatial working memory. Participants were required to
search through a set of red boxes on the screen in order to col-
lect blue tokens hidden inside the boxes and use them to fill an
empty column on the right-hand side of the screen. Touching a
box revealed whether or not it contained a blue token. Partici-
pants were instructed that only one token would be hidden at a
time and that their task was to search until it was found, at
which point the next token would be hidden. It was repeatedly
emphasised that once a blue token had been found, that par-
ticular box would not be used again to hide a token on that
trial. Every box was used once to hide a token so the total
number of blue tokens to be found on each trial was equal
to the total number of red boxes displayed on the screen.
There were four practice trials with three boxes and then
twelve test trials with four, six and eight boxes (four trials
at each level). The colour and position of the boxes used
were changed from trial to trial to discourage the use of stereo-
typed search strategies.
A ‘between-search error’ was recorded when a participant
returned to open a box in which a blue token had already been
found in a previous search, whereas a ‘within-search error’
was recorded when a participant returned to a box already
opened and shown to be empty in the same search sequence.
The three levels of difficulty (four, six and eight boxes) were
combined to produce the total number of errors (between þ
within) as the first dependent measure. Owen et al. (1990) ident-
ified a second dependent measure (‘strategy’) reflecting the
extent to which an efficient search strategy was adopted. This
involves a repetitive searching pattern in which participants
always begin with a particular box, search the boxes in a fixed
order, and then return to start each new sequence with the
same box when a token has been found. A strategy score was
determined on the basis of trials with six and eight boxes, with
higher scores reflecting poorer use of the strategy (less efficient
search) than lower scores.
Reaction time. There were two conditions in this task,
namely, simple reaction time and five-choice reaction time,
and they were always performed in that order. In the simple reac-
tion time task, participants were required to hold down the large
press-pad in front of them until a yellow dot appeared inside a
circle in the centre of the computer screen. At this point, partici-
pants had to release the press-pad and touch the yellow dot as
quickly as possible. The next dot appeared only after participants
had returned to hold down the press-pad again. In the five-choice
reaction time task, the yellow dot could appear in any one of five
circles arranged around the centre of the screen. Both tasks were
divided into practice and test phases, and participants were
required to obtain nine out of ten trials correct in the practice
phase before progressing to the test phase (fifteen trials per con-
dition). If participants failed to achieve this, they were allowed a
second practice phase but then had to proceed to the test phase
regardless of performance. (In fact, performance was highly
accurate in this task.) For each condition, there were two depen-
dent measures (correct trials only): (1) mean latency in ms from
the appearance of the stimulus to the release of the press-pad (i.e.
reaction time); (2) mean latency in ms from the release of the
press-pad to the touching of the stimulus (i.e. movement time).
Results were qualitatively similar for the simple and five-
choice tasks and so we present only the five-choice data here.
Matching to sample visual search. In this task, participants
viewed an abstract pattern, composed of four coloured elements,
in the centre of the screen. To obtain the sample pattern, partici-
pants were required to hold down the press-pad. Shortly after-
wards, two, four or eight similar patterns appeared in a circle
of boxes surrounding the original pattern. Participants were
required to release the press-pad and touch the single pattern
that exactly matched the pattern in the centre of the screen.
They were repeatedly encouraged not to release the press-pad
until they had decided which was the matching pattern. There
were three practice trials followed by eighteen test trials (six
trials with two, four and eight patterns, intermixed). There
were two dependent measures: (1) response accuracy (the total
number of correctly matched patterns out of eighteen, expressed
as a percentage); (2) mean latency in ms to release the press-pad
on the appearance of the test patterns for correct trials. As accu-
racy was high (93 % for both age groups) and there was no evi-
dence of a speed–accuracy trade-off, we present only the latency
data here.
Data analysis
Experimenters at one of the centres testing older adults (Gre-
noble, France) terminated the SWM task after completing the
six-box condition, thereby omitting the eight-box condition.
The main analyses of SWM data are therefore based on
reduced numbers of older adults (108 rather than 199). In
addition, the total number of participants for each measure
was not always 387 because of the very occasional early ter-
mination either of the CANTAB session or of a CANTAB task
within a session.
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Data were analysed using SPSS statistical software package
version 11.0 (SPSS Inc., Chicago, IL, USA). Baseline measures
(see Table 1) were entered into two-way ANOVA with age
group (younger v. older) and (subsequent) treatment (0, 15 and
30 mg/d) as between-subjects factors. The main analyses
(i.e. Zn and cognitive measures) were three-way repeated
measures ANOVA with age group (younger v. older) and treat-
ment (0, 15 and 30 mg/d) as between-subjects factors, and time
(0, 3 and 6 months) as a within-subjects factor. (Initial analyses
included centre (four levels: Coleraine; Clermont-Ferrand;
Rome; Grenoble) as a between-subjects factor. These revealed
few centre effects or interactions involving centre that could
not be attributed instead to differences in age between partici-
pants tested in Coleraine and Clermont-Ferrand (younger) v.
Rome and Grenoble (older). Therefore, data from centres testing
participants of the same age were combined in all the reported
analyses.) Where there was evidence of departure from the
sphericity assumption, Greenhouse–Geisser corrections are
reported. In addition, correlations were calculated between Zn
measures (intake and blood and urine levels) and cognitive
measures (MMSE and CANTAB scores) at baseline
(i.e. before supplementation), with age partialled out, separately
for males and females.
Results
Baseline measures
The younger group was on average approximately 12·5 years
younger than the older group but age did not differ significantly
between participants assigned to the three different treatments
(F , 1), and there was no age £ treatment interaction (F , 1).
For MMSE, there was no effect of age group (F(1, 381) 2·77;
P.0·05), or of treatment (F(2, 381) 1·90; P.0·1), and no inter-
action (F(2, 381) 1·74; P.0·1). There were also no significant
effects for geriatric depression scale: age (F , 1); treatment
(F(2, 381) 2·90; P.0·05); age £ treatment (F(2, 381) 1·05;
P.0·1). The ANOVA on Zn intake revealed no effect of age
group (F(1, 376) 2·59; P.0·1), or of treatment (F(2, 376)
1·13; P.0·1), and no interaction (F(2, 376) 1·91; P.0·1). For
serum Zn, there were no significant effects: age (F(1, 379)
1·94; P.0·1); treatment (F , 1); age £ treatment (F , 1).
Erythrocyte Zn levels were significantly higher in younger
than in older adults (F(1, 369) 13·46; P,0·001); there was no
effect of treatment (F , 1), and no interaction (F(2, 369) 1·76;
P.0·1). Urinary Zn levels were significantly lower in younger
than in older adults (F(1, 376) 37·09; P,0·001). There was
also a significant effect of treatment (F(2, 376) 3·23; P,0·05);
post hoc Scheffe´ tests revealed that only the difference between
the 0 and 30 mg/d groups reached significance (P,0·05). There
was no age £ treatment interaction (F(2, 376) 1·34; P.0·1). In
summary, participants in both age groups were reasonably well
matched across the three treatments on measures at baseline
(Table 1). Younger adults differed from older adults only in
terms of erythrocyte (higher) and urinary (lower) Zn levels.
Zinc measures
For both serum and urinary Zn, there were highly significant two-
way interactions between treatment and time (F(4, 758) 16·95,
P,0·001; F(3·6, 663) 12·43, P,0·001, respectively). Changes
between baseline (i.e. month 0) and months 3 and 6 (which
were themselves similar) for serum Zn were as follows: the pla-
cebo group dropped by 0·25mmol/l, the 15 mg/d group increased
by 1·02mmol/l, and the 30 mg/d group increased by 2·12mmol/l.
Corresponding changes for urinary Zn were a drop of 0·10mmol/
mmol creatinine (placebo), an increase of 0·13mmol/mmol crea-
tinine (15 mg/d) and an increase of 0·44mmol/mmol creatinine
(30 mg/d). The trends for erythrocyte Zn were similar
(23·15, þ 7·14 and þ8·16mmol/l, respectively), but the
treatment £ time interaction did not reach significance in this
case (F(4, 738) 1·79;P.0·1). These data demonstrate significant
biological consequences of Zn supplementation and provide con-
firmation of the participants’ compliance with the study’s
requirements. For all three measures, the three-way interaction
between age, treatment and time was not significant (all
P.0·1), indicating that younger and older adults reacted simi-
larly in biological terms to the Zn supplementation.
Cognitive measures
Zinc–cognition correlations at baseline. Out of seventy-two
correlations, only three reached significance at P,0·05
(r 0·187 between serum Zn and PRM latency for males;
r 20·155 between erythrocyte Zn and PRM latency for
males; r 0·164 between five-choice reaction time and erythro-
cyte Zn for females) and only one at P,0·01 (r 0·206 between
serum Zn and five-choice reaction time for males). Thus there
was no strong evidence of any consistent relationships
between Zn intake or blood and urine levels of Zn and cogni-
tive measures at baseline.
Age £ treatment £ time analysis of variance. First, for
each dependent measure, there was a highly significant
effect of age group (all P,0·001). Younger adults were
more accurate (PRM, SWM, spatial span), faster (PRM,
MTS, five-choice reaction time, five-choice movement time)
and more efficient (SWM strategy) than older adults (for over-
all means, see Table 2).
Second, there were significant main effects of time for
PRM accuracy (F(2, 760) 3·67; P¼0·026), PRM latency
(F(1·8, 681) 29·07; P,0·001), SWM total errors (F(1·9,
561) 35·21; P,0·001), SWM strategy (F(2, 580) 9·52;
P,0·001) and MTS latency (F(2, 736) 15·49; P,0·001),
mostly reflecting improvements with practice (see Fig. 1).
These differed significantly between younger and older
adults (i.e. age £ time interactions) for PRM accuracy (F(2,
760) 3·09; P¼0·046), SWM total errors (F(1·9, 561) 6·50;
P¼0·002) and MTS latency (F(2, 736) 4·50; P¼0·012). For
PRM, accuracy fell slightly between months 0 and 3 for
younger adults only (88, 86 and 86 % for months 0, 3, and
6 for younger adults; 82 % for months 0, 3 and 6 for older
adults). PRM latency decreased from 2703 to 2462 to
2382 ms from months 0 to 3 to 6. SWM errors decreased
over time, but more so for older adults (an overall drop of
twelve errors over 6 months) than for younger adults
(a drop of six). SWM strategy improved with practice
(35·5, 35·1 and 34·4 for months 0, 3 and 6). Finally, MTS
latency decreased over time, particularly for younger adults
(an overall decrease of 408 ms from months 0–6) compared
with older adults (a decrease of 134 ms).
Third, there were significant treatment £ time interactions for
SWM errors (F(3·9, 561) 2·74; P¼0·030) and MTS latency
E. A. Maylor et al.756
(F(3·9, 736) 3·15; P¼0·015). For SWM errors, the interaction
could be attributable to greater improvement from months 0 to
3 for the 15 and 30 mg/d treatments than for placebo and/or to
greater improvement from months 3 to 6 for the 0 and 15 mg/d
treatments than for the 30 mg/d treatment. Separate ANOVA
on months 0–3 and on months 3–6 both revealed significant
treatment £ time interactions (P¼0·046 and 0·014, respect-
ively). However, it is not clear from Fig. 1(c) that either the 15
or 30 mg/d treatment produced any substantial or lasting benefit
in terms of SWM errors over placebo. Note also that an ANOVA
on SWM errors from four and six boxes only (i.e. excluding eight
boxes and thereby reinstating the data from older adults tested in
Grenoble) produced no treatment £ time interaction (F , 1).
For MTS latency, the significant interaction was due to greater
improvement over the 6 months for the 0 and 30 mg/d treatments
than for the 15 mg/d treatment (see Fig. 1(f)). There was also a
marginal interaction for SWM strategy (F(4, 580) 2·31;
P¼0·057; Fig. 1(d)), with the 30 mg/d group showing less
improvement from 0 to 3 months than the other groups, but
this may reflect a ceiling effect as the 30 mg/d group had the
best strategy score of the three groups at baseline. Zn supplemen-
tation had no influence on PRM, spatial span or five-choice per-
formance. Note that, with a sample size of 387, of whom 257
received supplements, power was sufficiently high (.0·80) to
detect even a small effect size, given that the critical compari-
sons (i.e. performance before and after supplementation) were
essentially within-subjects.
Finally, there were no other significant effects. In particular,
there were no three-way (age £ treatment £ time) interactions,
indicating that the effects of Zn supplementation (such as they
were) did not differ significantly between younger and older
adults.
Discussion
To summarise the main findings, Zn intake at baseline was simi-
lar in younger and older adults (mean ages of 62 and 74 years,
respectively) but erythrocyte Zn was higher and urinary Zn
was lower in younger adults than in older adults, with no age
difference for serum Zn. There were almost no significant
associations between either Zn intake or status at baseline and
measures of cognitive function. Supplementation was effective
in that serum and urinary Zn levels both increased, and more
so for the higher dose (30 mg/d) than for the lower dose
(15 mg/d), with similar trends for erythrocyte Zn. These biologi-
cal effects of Zn supplementation did not differ between younger
and older adults. For the cognitive measures, younger adults out-
performed older adults on all tests. Crucially, however, there
were only two significant interactions indicating effects of Zn
supplementation on cognitive function, with a beneficial effect
(but only at 3 months) of 15 and 30 mg/d for SWM errors, and
a detrimental effect of 15 mg/d for MTS latency. Additional ana-
lyses not reported here showed that these findings were the same
for: (1) males and females; (2) lower and higher functioning
individuals (based on MMSE scores); (3) those with no/primary,
secondary and tertiary education; (4) individuals with lower and
higher Zn intakes and serum levels.
Zn intake was unaffected by age, which is perhaps surprising
in view of previous literature (see p. 752). It was slightly higher
overall at 10·9 mg/d than in a study of 2974 adults with a mean
age of 70 years whose average Zn intake was 9·9 mg/d (Ma &
Betts, 2000), and in the Age-Related Eye Disease Study
Research Group (2002) study of 3635 adults with a median
age of 69 years whose average Zn intake was 9·4 mg/d. RDA
for Zn appear to vary somewhat between countries and over
time – for example, US RDA can be found of 12 and 15 mg/d
for females and males, respectively (Food and Nutrition Board
& National Research Council, 1989), and 8 and 11 mg/d (Food
and Nutrition Board & Institute of Medicine, 2000). Based on
the more recent figures, the percentages of participants in the
present study whose Zn intake was less than two-thirds of the
RDA were small at 5·3 (females) and 8·8 (males). It seems
that, contrary to previous studies (for example, Briefel et al.
2000), Zn intake (at least as estimated from analysis of 4 d
food diaries) was adequate for the majority of our participants
(see also Andriollo-Sanchez et al. 2005).
Urinary Zn was higher in older adults than in younger adults,
suggesting changes in Zn metabolism with age. Erythrocyte but
not serum Zn decreased with age. The overall mean for serum Zn
of 13·1mmol/l was roughly comparable with the mean from the
Age-Related Eye Disease Study Research Group (2002) study of
12·7mmol/l. In the present study, the percentages of participants
Table 2. Overall measures for younger and older adults on tests from the Cambridge Automated Neuropsy-
chological Test Battery
(Mean values with their standard errors)
Younger*** Older***
Test Measure Mean SE Mean SE
PRM Accuracy (% correct) 86·80 0·60 82·02 0·58
PRM Mean correct latency (ms) 2293·30 48·93 2738·36 47·78
SWM Total errors 32·98 1·12 40·01‡ 1·47
SWM Strategy† 34·24 0·29 35·81‡ 0·39
SSP Span length 5·24 0·05 4·62 0·05
MTS Mean correct latency (ms) 2781·47 78·48 3878·98 77·02
Five-choice reaction time Mean correct latency (ms) 387·67 5·82 442·31 5·70
Five-choice movement time Mean correct latency (ms) 465·35 7·66 584·00 7·48
PRM, pattern recognition memory; SWM, spatial working memory; SSP, spatial span; MTS, matching to sample visual
search.
*** All differences between younger and older age groups were significantly different (P,0·001).
† A higher score indicates a less efficient strategy.
‡ Older adults’ data based on 108 participants rather than 199 (for details, see p. 755).
For details of subjects and procedures, see p. 753.
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Fig. 1. Mean scores on the Cambridge Automated Neuropsychological Test Battery immediately before Zn supplementation (0 months) and after 3 and 6 months
of supplementation for each of three treatments (0 (–X–), 15 (–O–) and 30 (–B–) mg/d) for (a) pattern recognition memory (PRM) accuracy (% correct), (b)
PRM mean correct latency (ms), (c) spatial working memory (SWM) total number of errors, (d) SWM strategy (for details, see p. 755), (e) spatial span, (f) match-
ing to sample visual search (MTS) mean correct latency (ms), (g) five-choice reaction time (RT) mean correct latency (ms) and (h) five-choice movement time
(MT) mean correct latency (ms). Data are means, with standard errors represented by vertical bars. For details of subjects and procedures, see p. 753.
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with a baseline serum Zn level below the accepted cut-off for Zn
deficiency of 10·7mmol/l (see Andriollo-Sanchez et al. 2005)
were 2·6 (females) and 2·1 (males). This low prevalence of Zn
deficiency contrasts with higher rates in other samples such as
hospitalised older adults (for example, Schmuck et al. 1996;
Pepersack et al. 2001).
The complete absence of any relationships between Zn
intake and cognitive measures (MMSE and CANTAB
scores) at baseline contrasts with the results of Ortega et al.
(1997). They found a significant, but relatively weak, corre-
lation between Zn intake and MMSE score that accounted
for less than 2 % of the variance. The present study employed
more sensitive cognitive measures and almost 50 % more par-
ticipants but failed to replicate the findings of Ortega et al.
(1997), which may indeed have been due to one of many poss-
ible confounding factors noted in their paper.
Age-related deficits were observed on all CANTAB
measures, as expected from previous studies (for example,
Robbins et al. 1994, 1998; Lowe & Rabbitt, 1998; Rabbitt
& Lowe, 2000; De Luca et al. 2003). There were significant
effects of repeated testing for some of the measures, particu-
larly between the first and second testing occasions (months
0 and 3). In one case, the younger adults benefited more
from practice than did the older adults, and in another case,
the opposite was true (for a discussion of related observations,
see Lowe & Rabbitt, 1998).
Importantly, there were few significant effects of Zn sup-
plementation on cognitive function – of the eight measures,
one showed a short-lived beneficial effect (but see p. 757) and
another showed a detrimental effect of 15 but not 30 mg/d.
This paucity of Zn effects was despite significant changes in bio-
logical measures (for example, serum Zn) showing at least
that participants had successfully taken the supplements as
instructed. There may be several explanations for the present
results. As already noted, we can rule out the possibility that par-
ticipants did not comply with the study’s requirements or that the
amounts of Zn (15 and 30 mg/d) were too low to have any mea-
surable effects. We can also probably discount a lack of power as
the explanation (see p. 757). Note further that the cognitive tests
employed were sufficiently challenging and sensitive to produce
marked age-related deficits. Perhaps more likely is the possi-
bility that the present participants were not sufficiently deficient
in Zn (either in terms of intake or serum levels) to gain much ben-
efit from supplements. Certainly, they were a highly selective
sample, with 49 % of the initial 842 volunteers being excluded
from the study at screening on the basis of cognitive impairment,
depression, pathological conditions, medications, and so on. We
therefore do not know whether the present results would gener-
alise to the less healthy half of the population who were excluded
from the study. Thus it remains possible that the results of Zn
supplementation on cognitive function would be more positive
in other, more vulnerable, populations (for example, cognitively
impaired or hospitalised older adults).
Although the present results revealed evidence of only one
beneficial effect of Zn supplements on cognitive function,
they also showed only one adverse effect. This is important
because older adults may take Zn supplements for non-cogni-
tive reasons – for example, the Age-Related Eye Disease
Study Research Group (2001) study showed that antioxidants
and Zn supplements reduced the progression of age-related
macular degeneration. It is also reassuring in view of the
growing availability and use of both fortified foods and diet-
ary supplements.
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